NCT06116630Recruiting
StrokeCog-BBB to Study Cognitive Outcomes Following Stroke
Source: ClinicalTrials.gov · Last updated 18 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to learn about cognitive outcomes in stroke patients. The main question it aims to answer are: 1. Is blood-brain barrier permeability compromised for years after stroke, 2. Is a blood biomarker of imbalanced angiogenesis dysregulated in chronic stroke and 3. Are there biomarkers that separately or together predicts cognitive decline after stroke, and are other MRI, blood, and clinical characteristics that are associated. Participants will undergo cognitive testing and MRIs two years apart. Researchers will compare cognitive outcomes in non-stroke patients who have cardiovascular risk factors to understand the effects of stroke on these outcomes.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 30 Oct 2023
- Start date
- 17 May 2022
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Stanford University
- Diseases
- Stroke
- NCT number
- NCT06116630
What you commit to
- Study type: Observational
- Planned participants: 350
- From 17 May 2022 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with IL-1 blockade or established immune-suppressant therapy (e.g. IL-1Ra or IL-1 antibodies), or treatment within the last 3 months
- No history of any previous ischaemic or haemorrhagic stroke, a mini-stroke or a serious brain injury
- Major neurological disease (immune mediated, previous brain tumors)
Other illness
- Do not have dementia
- Renovascular Disease
Other
- Currently participating in a clinical trial of investigation medicinal product (CTIMP) or device trial.
Who the study is looking for
- Aged 45 years or over
- One or more vascular risk factors (e.g. high blood pressure, diabetes or vascular disease such as angina, a previous heart attack, a heart bypass or peripheral artery disease in the legs)
- Established vascular disease (previous MI, angina, vascular stent in the peripheral bed)
- Sufficiently fluent in written and spoken English
- Living independently in the community
- Willing/able to give consent to study participation.
Age in the registry: 45 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University Hospital Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.